Research statistics

Afamelanotide research: publications and trials

What has been published on Afamelanotide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Afamelanotide works or is safe. For what it is and what the studies found, see the Afamelanotide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

124

Since 1988

Publications in 2026 so far

11

Through November 15, 2026

Human clinical research

31.7%

39 of 123 classified

Registered clinical trials

23

ClinicalTrials.gov

Randomized controlled trials

6

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

34.1%

20 animal · 20 in vitro · 2 computational

Records that only mention it

178

Not counted above

Status in the library: FDA-approved. Groups: Melanocortin agonists. 1 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Afamelanotide publications by year and evidence

1988, Preclinical (animal, in vitro, computational): 1 of 11990, Preclinical (animal, in vitro, computational): 1 of 11994, Preclinical (animal, in vitro, computational): 2 of 21995, Preclinical (animal, in vitro, computational): 1 of 11996, Preclinical (animal, in vitro, computational): 2 of 21997, Human clinical research: 1 of 21997, Preclinical (animal, in vitro, computational): 1 of 21998, Preclinical (animal, in vitro, computational): 1 of 21998, Reviews and meta-analyses: 1 of 22000, Human clinical research: 1 of 32000, Preclinical (animal, in vitro, computational): 2 of 32001, Preclinical (animal, in vitro, computational): 1 of 12003, Preclinical (animal, in vitro, computational): 1 of 12004, Human clinical research: 1 of 12005, Human clinical research: 1 of 42005, Preclinical (animal, in vitro, computational): 3 of 42007, Preclinical (animal, in vitro, computational): 2 of 22009, Human clinical research: 1 of 52009, Preclinical (animal, in vitro, computational): 1 of 52009, Reviews and meta-analyses: 1 of 52009, Other and not yet classified: 2 of 52010, Preclinical (animal, in vitro, computational): 2 of 52010, Reviews and meta-analyses: 3 of 52011, Human clinical research: 2 of 22012, Human clinical research: 1 of 42012, Preclinical (animal, in vitro, computational): 3 of 42013, Human clinical research: 2 of 52013, Preclinical (animal, in vitro, computational): 2 of 52013, Reviews and meta-analyses: 1 of 52014, Human clinical research: 1 of 32014, Reviews and meta-analyses: 1 of 32014, Other and not yet classified: 1 of 32015, Human clinical research: 3 of 72015, Other and not yet classified: 4 of 72016, Human clinical research: 1 of 62016, Preclinical (animal, in vitro, computational): 1 of 62016, Reviews and meta-analyses: 4 of 62017, Reviews and meta-analyses: 4 of 42018, Reviews and meta-analyses: 1 of 12019, Preclinical (animal, in vitro, computational): 3 of 62019, Reviews and meta-analyses: 2 of 62019, Other and not yet classified: 1 of 62020, Human clinical research: 3 of 72020, Preclinical (animal, in vitro, computational): 1 of 72020, Reviews and meta-analyses: 3 of 72021, Human clinical research: 3 of 92021, Preclinical (animal, in vitro, computational): 3 of 92021, Reviews and meta-analyses: 3 of 92022, Human clinical research: 3 of 42022, Reviews and meta-analyses: 1 of 42023, Human clinical research: 5 of 82023, Preclinical (animal, in vitro, computational): 2 of 82023, Reviews and meta-analyses: 1 of 82024, Human clinical research: 2 of 82024, Preclinical (animal, in vitro, computational): 2 of 82024, Reviews and meta-analyses: 2 of 82024, Other and not yet classified: 2 of 82025, Human clinical research: 4 of 62025, Reviews and meta-analyses: 1 of 62025, Other and not yet classified: 1 of 62026 (to date), Human clinical research: 4 of 112026 (to date), Preclinical (animal, in vitro, computational): 4 of 112026 (to date), Reviews and meta-analyses: 2 of 112026 (to date), Other and not yet classified: 1 of 11Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05101519882000201020172026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
198801001
199001001
199402002
199501001
199602002
199711002
199801102
200012003
200101001
200301001
200410001
200513004
200702002
200911125
201002305
201120002
201213004
201322105
201410113
201530047
201611406
201700404
201800101
201903216
202031307
202133309
202230104
202352108
202422228
202540116
2026 (to date)442111

Study types

Review30
Animal study20
In vitro study20
Observational human study16
Editorial, letter or other11
Other clinical trial10
Case report7
Randomized controlled trial6
Computational study2
Systematic review1
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Dermatology82
Metabolic health39
Gastrointestinal35
Oncology15
Neurological and mental health12
Immune system10
Tissue repair9
Obesity and weight management8
Cardiovascular5
Antimicrobial and infectious disease4
Endocrinology4
Cognitive health2

Registered clinical trials

5 of 18 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 18 · Unknown status: 4 · Active, not recruiting: 1
Phase not applicable: 1 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 12 · Phase 3: 6

TrialStatusPhaseStartedResults
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria PatientsNCT06388642 · 28 enrolledCompletedPhase 1, Phase 22024-03Posted
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoNCT06109649 · 200 enrolledActive, not recruitingPhase 32023-10—
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)NCT05854784 · 6 enrolledCompletedPhase 22023-03Posted
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the FaceNCT05210582 · 6 enrolledUnknown statusPhase 22022-10—
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and VNCT05370235 · 6 enrolledUnknown statusPhase 22022-03—
DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy VolunteersNCT05368857 · 10 enrolledCompletedPhase 12022-01—
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)NCT05159752 · 6 enrolledUnknown statusPhase 22021-10—
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)NCT04962503 · 6 enrolledCompletedPhase 22021-06Posted
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)NCT04525157 · 21 enrolledCompletedPhase 22014-06Posted
Phase III Confirmatory Study in Erythropoietic ProtoporphyriaNCT01605136 · 93 enrolledCompletedPhase 32012-05Posted
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental VitiligoNCT01382589 · 15 enrolledCompletedPhase 22011-09—
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)NCT04578496 · 16 enrolledCompletedPhase 32011-07Posted
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)NCT01430195 · 56 enrolledCompletedPhase 12011-06—
Afamelanotide in Patients Suffering With Acne VulgarisNCT04943159 · 3 enrolledCompletedPhase 22010-08Posted
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)NCT04704713 · 31 enrolledCompletedPhase 32010-05Posted
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)NCT01097044 · 77 enrolledCompletedPhase 22010-04Posted
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)NCT00979745 · 74 enrolledCompletedPhase 32009-09Posted
Implant Pharmacokinetic and Pharmacodynamic StudyNCT03634137 · 24 enrolledCompletedPhase 12009-09—
Phase II Solar Urticaria (SU) Pilot StudyNCT00859534 · 5 enrolledCompletedPhase 22008-12—
Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer SodiumNCT04425746 · 16 enrolledCompletedPhase 22008-08Posted
Phase II AK Study in Organ Transplant PatientsNCT00829192 · 200 enrolledUnknown statusPhase 22007-11—
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)NCT00472901 · 18 enrolledCompletedPhase not applicable2007-05—
Multicentre Phase III Erythropoietic Protoporphyria StudyNCT04053270 · 100 enrolledCompletedPhase 32007-05Posted

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · December 14, 2022 · Systematic review · cited 22 times · open access

    PMID 36525819 · DOI 10.1016/j.biopha.2022.114132 · Reviews and meta-analyses

  2. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.

    Journal of the American Academy of Dermatology · January 25, 2020 · Randomized controlled trial · cited 32 times

    PMID 31987791 · DOI 10.1016/j.jaad.2020.01.035 · Human clinical research

  3. Afamelanotide for Erythropoietic Protoporphyria.

    The New England journal of medicine · July 1, 2015 · Randomized controlled trial · cited 283 times · open access

    PMID 26132941 · DOI 10.1056/nejmoa1411481 · Human clinical research

  4. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

    JAMA dermatology · January 1, 2015 · Randomized controlled trial · cited 188 times · open access

    PMID 25230094 · DOI 10.1001/jamadermatol.2014.1875 · Human clinical research

  5. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.

    Peptides · November 15, 2005 · Randomized controlled trial · cited 35 times

    PMID 16293341 · DOI 10.1016/j.peptides.2004.12.038 · Human clinical research

  6. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.

    Archives of dermatology · July 1, 2004 · Randomized controlled trial · cited 58 times

    PMID 15262693 · DOI 10.1001/archderm.140.7.827 · Human clinical research

  7. Skin pigmentation and pharmacokinetics of melanotan-I in humans.

    Biopharmaceutics & drug disposition · April 1, 1997 · Randomized controlled trial · cited 44 times

    PMID 9113347 · DOI 10.1002/(sici)1099-081x(199704)18:3<259::aid-bdd20>3.0.co;2-x · Human clinical research

  8. Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.

    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · September 1, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42678656 · DOI 10.1007/s43630-026-00986-x · Human clinical research

  9. Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.

    Photochemistry and photobiology · March 2, 2026 · Other clinical trial · cited 0 times · open access

    PMID 41766687 · DOI 10.1111/php.70081 · Human clinical research

  10. A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.

    BMC neurology · July 26, 2023 · Other clinical trial · cited 4 times · open access

    PMID 37496004 · DOI 10.1186/s12883-023-03338-9 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Afamelanotide for Erythropoietic Protoporphyria.

    The New England journal of medicine · July 1, 2015 · Randomized controlled trial · cited 283 times · open access

    PMID 26132941 · DOI 10.1056/nejmoa1411481 · Human clinical research

  2. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.

    JAMA dermatology · January 1, 2015 · Randomized controlled trial · cited 188 times · open access

    PMID 25230094 · DOI 10.1001/jamadermatol.2014.1875 · Human clinical research

  3. Molecular determinants of ligand binding to the human melanocortin-4 receptor.

    Biochemistry · December 1, 2000 · In vitro study · cited 170 times

    PMID 11101306 · DOI 10.1021/bi001684q · In vitro studies

  4. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.

    Journal of pharmaceutical sciences · September 1, 1996 · Animal study · cited 160 times

    PMID 8877878 · DOI 10.1021/js960097g · Animal studies

  5. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria.

    The New England journal of medicine · January 1, 2009 · Editorial, letter or other · cited 127 times · open access

    PMID 19144952 · DOI 10.1056/nejmc0805682 · Commentary and other

Latest publications

  1. Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.

    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · September 1, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42678656 · DOI 10.1007/s43630-026-00986-x · Human clinical research

  2. NDP-MSH rescues LPS-induced neuroinflammation, synaptic deficits, and depressive-like behaviors in mice: involvement of MC1R-cAMP/PKA signaling.

    Frontiers in pharmacology · August 5, 2026 · Animal study · cited 0 times · open access

    PMID 42621255 · DOI 10.3389/fphar.2026.1895800 · Animal studies

  3. The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology · July 1, 2026 · Animal study · cited 0 times · open access

    PMID 42394403 · DOI 10.1096/fj.202600817r · Animal studies

  4. Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery.

    Journal of controlled release : official journal of the Controlled Release Society · April 16, 2026 · In vitro study · cited 3 times · open access

    PMID 41999898 · DOI 10.1016/j.jconrel.2026.114932 · In vitro studies

  5. Biodegradable polyurethane nerve conduits functionalized with NDP-MSH-loaded self-assembling peptide hydrogels for peripheral nerve regeneration.

    Journal of materials chemistry. B · March 11, 2026 · Animal study · cited 0 times

    PMID 41758331 · DOI 10.1039/d5tb02626a · Animal studies

  6. Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · March 6, 2026 · Observational human study · cited 1 times · open access

    PMID 41793078 · DOI 10.1111/ddg.15996 · Human clinical research

  7. Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.

    Photochemistry and photobiology · March 2, 2026 · Other clinical trial · cited 0 times · open access

    PMID 41766687 · DOI 10.1111/php.70081 · Human clinical research

  8. New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin.

    Expert opinion on pharmacotherapy · March 1, 2026 · Review · cited 0 times · open access

    PMID 41885813 · DOI 10.1080/14656566.2026.2651281 · Reviews and meta-analyses

  9. Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.

    Reports (MDPI) · February 16, 2026 · Case report · cited 0 times · open access

    PMID 41718315 · DOI 10.3390/reports9010065 · Human clinical research

  10. Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.

    Journal of pharmaceutical and biomedical analysis · January 14, 2026 · Editorial, letter or other · cited 0 times

    PMID 41547183 · DOI 10.1016/j.jpba.2026.117362 · Commentary and other

Browse all 124 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Afamelanotide; CUV1647; melanotan-1; Melanotan I; NDP-MSH; SCENESSE

((TITLE_ABS:"Afamelanotide" OR CHEM:"Afamelanotide") OR (TITLE_ABS:"CUV1647" OR CHEM:"CUV1647" OR TITLE_ABS:"CUV 1647" OR CHEM:"CUV 1647") OR (TITLE_ABS:"melanotan-1" OR CHEM:"melanotan-1" OR TITLE_ABS:"melanotan1" OR CHEM:"melanotan1") OR (TITLE_ABS:"Melanotan I" OR CHEM:"Melanotan I") OR (TITLE_ABS:"NDP-MSH" OR CHEM:"NDP-MSH") OR (TITLE_ABS:"SCENESSE" OR CHEM:"SCENESSE")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Afamelanotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/afamelanotide